CA2407050A1 - Vecteurs a base d'alphavirus destines a l'infection durable - Google Patents

Vecteurs a base d'alphavirus destines a l'infection durable Download PDF

Info

Publication number
CA2407050A1
CA2407050A1 CA002407050A CA2407050A CA2407050A1 CA 2407050 A1 CA2407050 A1 CA 2407050A1 CA 002407050 A CA002407050 A CA 002407050A CA 2407050 A CA2407050 A CA 2407050A CA 2407050 A1 CA2407050 A1 CA 2407050A1
Authority
CA
Canada
Prior art keywords
alphavirus
vector
rna
replicon
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002407050A
Other languages
English (en)
Inventor
John M. Polo
Thomas W. Dubensky, Jr.
Silvia Perri
Barbara A. Belli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of CA2407050A1 publication Critical patent/CA2407050A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des molécules d'acides nucléiques isolés qui comprennent le gène de la protéine non structurelle 2 d'alphavirus qui, intégré de manière fonctionnelle dans une particule de réplicon d'alphavirus, un système d'initiation du vecteur eucaryote à plusieurs couches, une structure de vecteur d'alphavirus ou un réplicon de vecteur d'ARN, fournit un phénotype non cytopathique ou confère la capacité de mettre en oeuvre une réplication durable. L'invention concerne aussi des réplicons de vecteur d'ARN, des structures de vecteur d'alphavirus, des particules de réplicon d'alphavirus et des systèmes d'initiation du vecteur eucaryote à plusieurs couches qui contiennent des molécules des acides nucléiques identifiés ci-dessus ainsi que des procédés pour utiliser ces réplicons, structures, particules et systèmes d'initiation du vecteur eucaryote à plusieurs couches à des fins d'expression de protéines recombinantes.
CA002407050A 2000-04-25 2001-04-25 Vecteurs a base d'alphavirus destines a l'infection durable Abandoned CA2407050A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19957900P 2000-04-25 2000-04-25
US60/199,579 2000-04-25
PCT/US2001/013255 WO2001081553A1 (fr) 2000-04-25 2001-04-25 Vecteurs a base d'alphavirus destines a l'infection durable

Publications (1)

Publication Number Publication Date
CA2407050A1 true CA2407050A1 (fr) 2001-11-01

Family

ID=22738142

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002407050A Abandoned CA2407050A1 (fr) 2000-04-25 2001-04-25 Vecteurs a base d'alphavirus destines a l'infection durable

Country Status (3)

Country Link
US (1) US20030170871A1 (fr)
CA (1) CA2407050A1 (fr)
WO (1) WO2001081553A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423544B1 (en) * 1998-12-31 2002-07-23 Chiron Corporation Compositions and methods for producing recombinant virions
US7141425B2 (en) 2001-08-22 2006-11-28 Maxcyte, Inc. Apparatus and method for electroporation of biological samples
CN107033243B (zh) 2005-03-23 2020-12-15 根马布股份公司 用于治疗多发性骨髓瘤的cd38抗体
ES2304880B1 (es) * 2007-04-03 2009-10-27 Proyecto De Biomedicina Cima, S.L. Uso de un vector viral mutado para la generacion in vitro de lineas celulares estables.
KR101383476B1 (ko) 2007-11-01 2014-04-11 아스테라스 세이야쿠 가부시키가이샤 면역억제 폴리펩티드 및 핵산
ES2523016B1 (es) 2013-05-20 2015-09-09 3P Biopharmaceuticals Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes
EP2878674A1 (fr) 2013-11-28 2015-06-03 Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) Épisomes stables sur la base des vecteurs lentiviraux non intégratifs
AU2016355191B2 (en) 2015-11-18 2023-06-29 Orbis Health Solutions Llc T7 alpha viral vector system
AU2019315577A1 (en) * 2018-08-03 2021-03-25 Uab Research Foundation Methods and compositions for alphavirus vaccine
AU2022238403A1 (en) * 2021-03-19 2023-09-21 Tiba Biotech Llc Artificial alphavirus-derived rna replicon expression systems

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792462A (en) * 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems

Also Published As

Publication number Publication date
WO2001081553A1 (fr) 2001-11-01
US20030170871A1 (en) 2003-09-11

Similar Documents

Publication Publication Date Title
US6329201B1 (en) Compositions and methods for packaging of alphavirus vectors
EP1141361B1 (fr) Compositions et methodes permettant l'encapsidation de vecteurs d'alphavirus
DRYGA et al. Identification of mutations in a Sindbis virus variant able to establish persistent infection in BHK cells: the importance of a mutation in the nsP2 gene
US6224879B1 (en) Alphavirus expression vector
CN1989250B (zh) Tc-83衍生的甲病毒属载体、颗粒和方法
JP4383530B2 (ja) 細胞巨大分子合成の阻害が減少したアルファウイルスベクター
JP4790984B2 (ja) アルファウイルスレプリコンベクター系
US20100330121A1 (en) Recombinant alphavirus-based vectors with reduced inhibition of cellular macro-molecular synthesis
WO1997038087A9 (fr) Vecteurs a base d'alphavirus de recombinaison, presentant une inhibition reduite de la synthese macromoleculaire cellulaire
US6943015B2 (en) Large scale production of packaged alphavirus replicons
WO2008119827A1 (fr) Produits de synthèse transréplicases
EP2097533B9 (fr) Vecteur viral et ses applications
US20030170871A1 (en) Alphavirus-based vectors for persistent infection
Casales et al. Development of a new noncytopathic Semliki Forest virus vector providing high expression levels and stability
Schlesinger Alphavirus expression vectors
CN101589150B (zh) 病毒载体及其应用
NO342179B1 (no) cDNA construct of Salmonidae alphavirus
US20110130304A1 (en) Method for creating a viral genomic library, a viral genomic library and a kit for creating the same
US20080096274A1 (en) Recombinant alphavirus vectors and methods of using same
Herrmann et al. Recombination of nonreplicative RNA precursors of sindbis virus in infected cells overexpressing murine-inducible nitric oxide synthase
CA2719413A1 (fr) Compositions et methodes permettant l'encapsidation de vecteurs d'alphavirus

Legal Events

Date Code Title Description
FZDE Discontinued